Braveheart Bio Strengthens Leadership with Emil deGoma, M.D. as CMO for Innovative Cardiovascular Therapeutics Braveheart Bio appoints Dr. Emil deGoma as Chief Medical Officer to lead clinical strategy and advance the development of BHB-1893 for heart diseases.

Braveheart Bio Strengthens Leadership with Emil deGoma, M.D. as CMO for Innovative Cardiovascular Therapeutics #USA #San_Francisco #Braveheart_Bio #BHB-1893 #Emil_deGoma